<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01295879</url>
  </required_header>
  <id_info>
    <org_study_id>AAAF3346</org_study_id>
    <nct_id>NCT01295879</nct_id>
  </id_info>
  <brief_title>Vitamin D Repletion in Stone Formers With Hypercalciuria</brief_title>
  <official_title>Effect of Ergocalciferol Repletion on Urine Calcium Among Stone Formers With Vitamin D Deficiency and Hypercalciuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Presbyterian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Presbyterian Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D plays a critical role in maintaining bone health, as well as preventing
      cardiovascular disease, cancer, and various autoimmune diseases, such as diabetes. Vitamin D
      deficiency is very common in the United States and worldwide, and is now being increasingly
      recognized and treated. One group in which vitamin D deficiency may be particularly important
      is patients who have had kidney stones. These patients frequently have elevated levels of
      calcium in their urine, which is a common and important risk factor for calcium containing
      kidney stones. Because vitamin D increases absorption of calcium into the blood by the
      intestines, physicians may be reluctant to prescribe vitamin D therapy to patients with
      vitamin D deficiency if they also have kidney stones and high amounts of calcium in the
      urine. They are concerned about the possible risk of increasing the amount of calcium in the
      urine (and thereby increasing the risk of calcium stones occurring again). However, studies
      in patients without kidney stones, as well as studies in patients with high calcium levels in
      the urine, have demonstrated that giving vitamin D is effective and safe and does not
      increase calcium in the urine. Therefore, the investigators will study the effects of giving
      vitamin D on the amount of calcium in the urine in patients with a history of kidney stones
      and elevated calcium in the urine. The investigators will evaluate the safety of giving
      vitamin D to this particular group of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to conduct a clinic-based interventional study of 30 patients followed
      at outpatient urology clinics associated with New York Presbyterian Hospital (NYPH). The
      intervention is supplementation with oral ergocalciferol 50,000 IU per week for 8 weeks, and
      each participant will serve as his/her own control. The formulation, dose, and duration of
      vitamin D therapy is reflective of that which is given in routine clinical practice to
      patients with vitamin D deficiency. The outcome is the change in urinary calcium excretion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 24 Hour Urine Calcium</measure>
    <time_frame>8 weeks</time_frame>
    <description>Elevated values of urine calcium are a risk factor for recurrence of calcium kidney stones</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 24 Hour Urine Supersaturation of Calcium Oxalate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Elevated values of calcium oxalate supersaturation in the urine are a risk factor for recurrence of calcium kidney stones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of Kidney Stones</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Nephrolithiasis</condition>
  <condition>Urolithiasis</condition>
  <condition>Idiopathic Hypercalciuria</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Disorder of Vitamin D</condition>
  <arm_group>
    <arm_group_label>Ergocalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergocalciferol</intervention_name>
    <description>Ergocalciferol 50,000 IU's orally per week, for 8 weeks</description>
    <arm_group_label>Ergocalciferol</arm_group_label>
    <other_name>Vitamin D2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of nephrolithiasis as per medical record

          -  Urinary calcium excretion between 150 and 400 mg/day (measured within 3 months of
             study enrollment)

          -  25(OH)D deficiency or insufficiency (defined as a serum level &lt; 30 ng/ml) within 3
             months of enrollment

        Exclusion Criteria:

          -  Pregnant women, since the optimal dose of vitamin D supplementation in this population
             has not been rigorously studied.

          -  Known uric acid, cystine, or struvite stone disease (because our intervention is
             predominantly aimed at patients with calcium stone disease). An exception to this is
             patients who have passed both uric acid and calcium stones, or patients who have
             passed stones of mixed composition (uric acid and calcium).

          -  Hypercalcemia (serum calcium &gt; 10.4 mg/dL) at baseline

          -  Acute stone event or gross hematuria (blood in the urine) within the past 2 months

          -  Recent stone intervention within the past 1 month

          -  Suspected or known secondary causes of hypercalciuria, such as primary
             hyperparathyroidism, sarcoidosis, hyperthyroidism, or malignancy (except nonmelanoma
             skin cancer)

          -  Addition or dose change of medicines potentially affecting urinary calcium since the
             baseline 24hour urine collection (including diuretics, magnesium supplements,
             potassium supplements, potassium citrate, and vitamin D supplementation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <results_first_submitted>September 10, 2012</results_first_submitted>
  <results_first_submitted_qc>September 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2012</results_first_posted>
  <last_update_submitted>September 10, 2012</last_update_submitted>
  <last_update_submitted_qc>September 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Presbyterian Hospital</investigator_affiliation>
    <investigator_full_name>David E. Leaf</investigator_full_name>
    <investigator_title>Nephrology Fellow</investigator_title>
  </responsible_party>
  <keyword>Vitamin D insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Hypercalciuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ergocalciferol</title>
          <description>Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ergocalciferol</title>
          <description>Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in 24 Hour Urine Calcium</title>
        <description>Elevated values of urine calcium are a risk factor for recurrence of calcium kidney stones</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ergocalciferol</title>
            <description>Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 24 Hour Urine Calcium</title>
          <description>Elevated values of urine calcium are a risk factor for recurrence of calcium kidney stones</description>
          <units>mg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 24 Hour Urine Supersaturation of Calcium Oxalate</title>
        <description>Elevated values of calcium oxalate supersaturation in the urine are a risk factor for recurrence of calcium kidney stones</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ergocalciferol</title>
            <description>Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 24 Hour Urine Supersaturation of Calcium Oxalate</title>
          <description>Elevated values of calcium oxalate supersaturation in the urine are a risk factor for recurrence of calcium kidney stones</description>
          <units>(unitless)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence of Kidney Stones</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ergocalciferol</title>
            <description>Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence of Kidney Stones</title>
          <units># of stone recurrences</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ergocalciferol</title>
          <description>Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David E. Leaf, M.D., Renal Fellow</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-732-5951</phone>
      <email>DELEAF@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

